AU2002302713A1 - Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof - Google Patents

Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof

Info

Publication number
AU2002302713A1
AU2002302713A1 AU2002302713A AU2002302713A AU2002302713A1 AU 2002302713 A1 AU2002302713 A1 AU 2002302713A1 AU 2002302713 A AU2002302713 A AU 2002302713A AU 2002302713 A AU2002302713 A AU 2002302713A AU 2002302713 A1 AU2002302713 A1 AU 2002302713A1
Authority
AU
Australia
Prior art keywords
mixture
peptides derived
papillomavirus proteins
papillomavirus
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002302713A
Other languages
English (en)
Inventor
Isabelle Bourgault-Villada
Jean-Gerard Guillet
Bernard Maillere
Sandra Pouvelle-Moratille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Commissariat a lEnergie Atomique CEA
Publication of AU2002302713A1 publication Critical patent/AU2002302713A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AU2002302713A 2001-05-04 2002-05-03 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof Abandoned AU2002302713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/05980 2001-05-04
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
PCT/FR2002/001533 WO2002090382A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Publications (1)

Publication Number Publication Date
AU2002302713A1 true AU2002302713A1 (en) 2002-11-18

Family

ID=8862980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002302713A Abandoned AU2002302713A1 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof

Country Status (7)

Country Link
US (2) US7488791B2 (enExample)
EP (1) EP1383535A2 (enExample)
JP (1) JP2005505503A (enExample)
AU (1) AU2002302713A1 (enExample)
CA (1) CA2446062A1 (enExample)
FR (1) FR2824326B1 (enExample)
WO (1) WO2002090382A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE10336916B4 (de) * 2003-08-07 2015-02-19 Danfoss A/S Regelventil und Wärmetauscheranordnung
US7576323B2 (en) * 2004-09-27 2009-08-18 Johns Hopkins University Point-of-care mass spectrometer system
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA3016942C (en) 2007-05-31 2022-09-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
ES2712505T3 (es) 2008-04-17 2019-05-13 Pds Biotechnology Corp Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
EP3058956A1 (en) 2015-02-23 2016-08-24 Institut Curie Combined vaccination/radioterapy for cancer treatment
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
MY189551A (en) 2016-06-20 2022-02-16 Isa Pharmaceuticals B V Formulation of a peptide vaccine
EP3267119A1 (en) 2016-07-07 2018-01-10 E.ON Sverige AB Combined heating and cooling system
MX2019003961A (es) * 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
US20210046114A1 (en) * 2018-01-24 2021-02-18 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
EP3784688A2 (en) * 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗
CN115461063A (zh) * 2020-02-10 2022-12-09 约翰霍普金斯大学 使用同种异体肿瘤特异性cd4+t细胞输注的癌症免疫疗法
WO2022159652A1 (en) * 2021-01-21 2022-07-28 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses for treating mucosal carcinomas
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
CN119569831A (zh) * 2024-12-13 2025-03-07 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
EP0523391B1 (en) * 1991-07-13 2003-03-19 Dade Behring Marburg GmbH Use of HPV-16 E6 and E7-gene derived peptides for the diagnostic purpose
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
EP1044019A1 (en) * 1998-01-09 2000-10-18 Circassia Limited Methods and compositions for desensitisation
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
AU785319B2 (en) * 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導

Also Published As

Publication number Publication date
US20040170644A1 (en) 2004-09-02
EP1383535A2 (fr) 2004-01-28
US20100203080A1 (en) 2010-08-12
FR2824326A1 (fr) 2002-11-08
FR2824326B1 (fr) 2004-03-19
WO2002090382A3 (fr) 2003-10-02
CA2446062A1 (fr) 2002-11-14
US7488791B2 (en) 2009-02-10
WO2002090382A2 (fr) 2002-11-14
JP2005505503A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2002302713A1 (en) Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
AU2002365258A1 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
AU2002324649A1 (en) Haplotype map of the human genome and uses therefor
AU2000275763A1 (en) Expression of functional eukaryotic proteins
AU2003241103A1 (en) Compositions containing anti-hiv peptides and methods of use
AU2003246614A1 (en) Novel use of lipopeptide preparations
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
AU2002311620A1 (en) Methods of making and using expression constructs for the expression of recombinant proteins
AU2002357382A1 (en) Compositions and methods relating to endometrial specific genes and proteins
AUPR595601A0 (en) Hypoglycaemic peptides and methods of use thereof
AU2002346056A1 (en) Viral proteins capable of binding lar
AU2002331780A1 (en) Compositions and methods relating to lung specific genes and proteins
AU2001277750A1 (en) Use of polypeptide
AU2002240921A1 (en) Medane genes and proteins
AU2002339859A1 (en) Compositions and methods relating to colon specific genes and proteins
AU2002352698A1 (en) Immune-related proteins and the regulation of the same
AU2002364105A1 (en) Compositions and methods relating to endometrial specific genes and proteins
AU2002357391A1 (en) Compositions and methods relating to endometrial specific genes and proteins
AU2002359817A1 (en) Compositions and methods relating to gastric specific genes and proteins
AU2002332760A1 (en) Compositions and methods relating to ovary specific genes and proteins
AU2002366640A1 (en) Detection and removal of lead using lead-binding proteins
AU2002351636A1 (en) Genes and proteins involved in the biosynthesis of lipopeptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase